Anti-TGF-β antibodies and their use

US10766955B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Gary Shapiro · Arlington, US
• Kevin Brower · Bound Brook Junction, US
• Patrick Finn · North Riverside, US
• Richard C. Gregory · Framingham, US
• Rao Koduri · Shrewsbury, US
• Feng Liu · Sunnyvale, US
• Natalia Malkova · Needham, US
• Parminder Mankoo · Foster City, US
• Jack R. Pollard · Acton, US
• Huawei Qiu · Westborough, US
• Joachim Theilhaber · Cambridge, US
• Christopher Winter · Swampscott, US
• Marcella Yu · Medford, US

Key dates

• Filing date: Jan 19, 2018
• Grant date: Sep 8, 2020
• Expiry date: Aug 3, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides an improved pan-TGF-β antibody for treatment of conditions that are mediated by TGF-β, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.